研究单位：[1]Daiichi Sankyo,Inc.[2]The First Affiliated Hospital of Xinjiang Medical University Ürümqi,Xinjiang Province,China[3]Xuanwu Hospital Capital Medical University Beijing,Xuanwu District,China[4]Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai,Xuhui District,China[5]Shanghai Jiaotong University Affiliated Sixth People'S Hospital Shanghai,Xuhui District,China[6]Zhongshan Hospital,Fudan University Shanghai,Xuhui District,China[7]Shanghai Yangpu East Hospital Shanghai,Yangpu District,China
研究目的：
The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.
